Abituzumab in SSc-ILD
Public ClinicalTrials.gov record NCT02745145. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
Study identification
- NCT ID
- NCT02745145
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Enrollment
- 24 participants
Conditions and interventions
Interventions
- Abituzumab 1500 mg Drug
- Abituzumab 500 mg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2016
- Primary completion
- May 29, 2018
- Completion
- May 29, 2018
- Last update posted
- Jun 17, 2019
2016 – 2018
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research site 1 | Los Angeles | California | 90045 | — |
| Research site | Los Angeles | California | 90095-1690 | — |
| Research site | Farmington | Connecticut | 06030 | — |
| Research site | Washington D.C. | District of Columbia | 20007 | — |
| Research site | Orlando | Florida | 32803 | — |
| Research site | Weston | Florida | 33331 | — |
| Research site | Chicago | Illinois | 60611 | — |
| Research site 1 | Boston | Massachusetts | 02114 | — |
| Research site 2 | Boston | Massachusetts | 02118 | — |
| Research site | Ann Arbor | Michigan | 48109-5360 | — |
| Research site | New Brunswick | New Jersey | 08901 | — |
| Research site | Great Neck | New York | 11021 | — |
| Research site 1 | New York | New York | 10021 | — |
| Research site 2 | New York | New York | 10032 | — |
| Research site | Portland | Oregon | 97239 | — |
| Research site | Nashville | Tennessee | 37232 | — |
| Research site | Dallas | Texas | 75246 | — |
| Research site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02745145, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 17, 2019 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02745145 live on ClinicalTrials.gov.